Medigen Vaccine Biologics Corporation (TPEX:6547)

Market Cap	16.04B
Revenue (ttm)	605.64M
Net Income (ttm)	-80.47M
Shares Out	328.75M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	37.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	853,790
Average Volume	2,181,922
Open	48.50
Previous Close	48.35
Day's Range	48.00 - 49.00
52-Week Range	33.70 - 57.00
Beta	1.09
RSI	52.45
Earnings Date	May 5, 2025

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2024, Medigen Vaccine Biologics's revenue was 605.64 million, an increase of 55.44% compared to the previous year's 389.62 million. Losses were -80.47 million, -93.06% less than in 2023.